Carrageenan-based Drug-Delivery Vehicle Development Service

Carrageenan (CG)-based Drug-Delivery Vehicle Development Service at CD BioGlyco

CG is a naturally occurring anionic sulfated polysaccharide extracted primarily from algae, which usually contains three structures: λ-CG, κ-CG, and ι-CG, they have good biocompatibility and low toxicity and are used as suitable drug vehicles. Based on this, CD BioGlyco provides a specialized CG-based drug delivery vehicle development service, thereby providing an effective means to improve the bioavailability, stability, and controlled release behavior of drugs. Our service content includes but is not limited to the following.

• CG-based nanoparticle vehicle development: We use different preparation methods to prepare CG nanoparticles, which have a small particle size, high specific surface area, and good stability, and are used for drug encapsulation and targeted delivery.
  • Solution method: We dissolve CG in an appropriate solvent, disperse it evenly through stirring, ultrasonic treatment, etc., and then undergo appropriate processes (such as pH adjustment, heating, cooling, etc.) to form nano-sized particles.
  • Precipitation method: We dissolve CG in water, add a precipitant (such as ethanol), form nanoparticles through precipitation, and then perform washing and drying steps.
  • CG-based hydrogel vehicle development
  We take advantage of CG to easily form gels and use solution preparation or ion cross-linking methods to prepare it into a hydrogel form as a drug delivery vehicle. This gel forms a three-dimensional network structure in water, which encapsulates drugs and achieves controlled release. For example, we have developed a CG hydrogel-based wound dressing, which encapsulates drugs in the gel and uses the temperature sensitivity of the gel to achieve a gradual release of the drug.
• CG-based liposome vehicle development: We dissolve CG and liposome components (such as phospholipid-like substances) in an organic solvent and then remove the solvent through membrane dissolution methods (such as rotary evaporation, membrane filtration, etc.) to form CG-based liposomes. Liposomes provide a bilayer membrane structure that entraps both water-soluble and lipid-soluble drugs.
• CG-based microsphere vehicle development: Methods for preparing CG microspheres include the ion gel method and emulsion polymerization method. In the ion gel method, we mix CG with a cationic cross-linking agent (such as calcium ions) to form a microsphere structure. In the emulsion polymerization method, we blend CG with other monomers (such as acrylic acid) and polymerize under the action of emulsifiers to form microspheres. These microspheres have good controlled release properties and are used to slowly release drugs and extend their effectiveness.
• CG-based micellar vehicle development: We mix CG with surfactants (such as Tween 80, SDS, etc.) and prepare micelles through solution mixing, sonication, or high-pressure homogenization.
• CG-based nanofiber vehicle development: We mix CG with polymers (such as chitosan, and cellulose) and prepare nanoscale CG fibers through electrospinning or template methods. These nanofibers have high specific surface area and good stability and are used for controlled drug delivery.
• Vehicle characterization and analysis service: We provide professional characterization and analysis for CG-based drug delivery vehicles, including particle size measurement, drug loading determination, stability evaluation, controlled release performance testing, etc., to ensure the quality and performance of drug vehicles.

In addition, CD BioGlyco has a diversified marine carbohydrates-based professional technology development solution, and we also provide λ-Carrageenan Adjuvant Development and Carrageenan-based Tissue Scaffold Development services.

Fig.1 CG-based drug-delivery vehicle development service. (CD BioGlyco)

Publication

Technology: In situ synthesis

Journal: Materials Science and Engineering: C

IF: 8.457

Published: 2018

Results: The authors gradually added the magnetic chitosan dispersion to the κ-carrageenan solution, and prepared a magnetic chitosan/κ-carrageenan vehicle containing the anticancer drug sunitinib by adjusting the pH value. At the same time, the authors conducted vehicle characterization and drug release studies. The results showed that the release of sunitinib from the magnetic vehicle was pH-dependent, with minimal drug release at pH = 7.4, indicating that this magnetic vehicle may become a candidate for anticancer drugs with reduced side effects.

Fig.2 Release profile of sunitinib in the vehicle. (Karimi, et al., 2018)

Applications

• Wound repair materials: CG is applied to prepare wound repair materials, such as dressings or biological glues. These materials release drugs to promote wound healing, reduce the risk of infection, and provide an appropriately moist environment to accelerate the wound healing process.
• Oral care: CG vehicles are used in oral care products such as rinses, gels, or patches. These products deliver drugs to the oral mucosal surfaces and are used to treat oral problems such as canker sores, gingivitis, and periodontal disease.
• Anti-infectious applications: CG is used to prepare antimicrobial drug delivery systems such as antibacterial dressings or topical products. These systems provide sustained drug release at the site of infection, inhibit pathogen growth, and promote wound healing.

Advantages

• CD BioGlyco has technical experts and R&D teams with an in-depth understanding of CG and drug delivery system development, we maturely apply it to the development of drug delivery vehicles.
• CD BioGlyco provides custom CG-based drug delivery vehicle development services according to client needs and goals, which include the ability to design appropriate vehicles based on drug characteristics and requirements, regulate drug release rates and modes, and achieve targeted delivery to specific tissues or cells.
• CD BioGlyco conducts a comprehensive performance evaluation of CG-based drug delivery vehicles, including testing and analysis of drug encapsulation efficiency, release rate, stability, biocompatibility, and cytotoxicity to ensure the safety and effectiveness of the vehicle.

CD BioGlyco has advanced technical means to support CG-based material preparation, performance evaluation, and drug delivery testing. We design and develop specific CG-based drug delivery vehicles according to client needs. Please feel free to contact us if you would like to consult detailed content.